Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.79 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.79 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MDK | P21741 | 3/20 | 0.44 |
| ▸ | BDNF | P23560 | 3/20 | 0.44 |
| ▸ | PTN | P21246 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CD69 | Q07108 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | IGF2R | P11717 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14266900 | 1.00 | LGALS3 (0.79) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL14266909 | 0.94 | LGALS3 (0.88) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL12880840 | 0.94 | LGALS3 (0.88) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL14355305 | 0.94 | LGALS3 (0.88) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL14380157 | 0.94 | LGALS3 (0.88) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL13736745 | 0.93 | LGALS3 (0.87) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL14266918 | 0.92 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL10026220 | 0.90 | LGALS3 (0.71) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL10060391 | 0.90 | LGALS3 (0.71) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL13734988 | 0.89 | LGALS3 (0.77) | LGALS3LGALS8LGALS4MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275007-A1 | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN S (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275007-A1 | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer | CA14, CA13, CA12 | LGALS3 13/4885LGALS8 36/4885LGALS4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.